Status:
NOT_YET_RECRUITING
PIMS vs PGT-A in Infertile PCOS Patients
Lead Sponsor:
First Affiliated Hospital, Sun Yat-Sen University
Collaborating Sponsors:
The Third Affiliated Hospital of Guangzhou Medical University
Guangdong Provincial Maternal and Child Health Hospital
Conditions:
PGT-A
PCOS
Eligibility:
FEMALE
20-40 years
Phase:
NA
Brief Summary
This experiment has become a serious issue for two reasons: DNA methylation plays an important role during embryogenesis, global abnormal methylome reprogramming often occurs in human embryos, and DNA...
Eligibility Criteria
Inclusion
- Women aged between 20 and 40 years diagnosed with PCOS according to international evidence-based guidline for assessment and management of policystic ovarian syndrome 2018.
- Women who plan to undergo the 1st/2nd IVF/ICSI/PGT-A treatment cycle.
- Women who obtain 2 or more blastocysts that have morphological score of 4BC/4CB or better on Day 5of embryo culture.
- Culture all the cleavage stage embryos into blastocysts, conduct biopsy on all the blastocysts, and cryopreserve each blastocyst as a single embryo
- Agree to the thawing and transfer of a single blastocyst.
- Sign the informed consent form.
Exclusion
- Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, or endometrial polyp(s); or with history of intrauterine adhesions.
- Women who are indicated and planned to undergo preimplantation genetic testing for structural rearrangements (PGT-SR) or preimplantation genetic testing for monogenic (PGT-M).
- Women who use donated oocytes or sperm to achieve pregnancy.
- Women with contraindication for assisted reproductive technology or for pregnancy, such as undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected carcinoma including including cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding and so on.
- Untreated hydrosalpinx according to ultrasonography test.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
766 Patients enrolled
Trial Details
Trial ID
NCT06887881
Start Date
May 1 2025
End Date
December 1 2028
Last Update
May 9 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.